OTC Markets OTCPK - Delayed Quote USD
Trevena, Inc. (TRVN)
1.2100
+0.0600
+(5.22%)
At close: May 9 at 2:08:54 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Carrie L. Bourdow | President, CEO & Chairman | 1.08M | -- | 1963 |
| Mr. Barry Shin J.D., M.B.A. | Chief Operating Officer | 722.79k | -- | 1972 |
| Dr. Mark A. Demitrack M.D. | Senior VP & Chief Medical Officer | 741.35k | -- | 1958 |
| Dr. Howard A. Rockman M.D. | Scientific Founder, Consultant and Member of Scientific Advisory Board | -- | -- | -- |
| Ms. Katrine Sutton | Principal Financial Officer & principal accounting officer | -- | -- | 1976 |
| Mr. Robert T. Yoder | Senior VP, Chief Business Officer, Head of Commercial Operations & Chief Compliance Officer | 490.64k | -- | 1966 |
| Mr. Michael Catalano | Vice President of Marketing | -- | -- | -- |
Trevena, Inc.
955 Chesterbrook Boulevard
Suite 110
Chesterbrook, PA 19087
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 23
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Corporate Governance
Trevena, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 12, 2025 at 12:30 PM UTC - May 16, 2025 at 12:30 PM UTC
Trevena, Inc. Earnings Date
Recent Events
Related Tickers
TCON TRACON Pharmaceuticals, Inc.
0.0322
0.00%
MTEM Molecular Templates, Inc.
0.0001
0.00%
CLRB Cellectar Biosciences, Inc.
0.2474
-1.63%
PXMD PaxMedica, Inc.
0.0001
0.00%
IPHA Innate Pharma S.A.
2.4386
+2.46%
LPCN Lipocine Inc.
3.2750
-1.65%
RLYB Rallybio Corporation
0.2930
0.00%
RGBP Regen BioPharma, Inc.
0.0580
0.00%
ENSC Ensysce Biosciences, Inc.
2.1700
+4.33%
NERV Minerva Neurosciences, Inc.
1.6100
-0.62%